NeuroOne Medical Technologies Co. (NASDAQ:NMTC) Short Interest Update

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 134,000 shares, a decline of 34.4% from the February 28th total of 204,300 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily trading volume, of 212,400 shares, the days-to-cover ratio is presently 0.6 days.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ:NMTC traded down $0.01 during mid-day trading on Monday, hitting $0.85. 73,253 shares of the company traded hands, compared to its average volume of 146,700. The firm’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $0.94. NeuroOne Medical Technologies has a 52-week low of $0.55 and a 52-week high of $1.39. The firm has a market cap of $26.24 million, a P/E ratio of -3.27 and a beta of 0.48.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Wednesday, February 12th. The company reported $0.06 earnings per share for the quarter. NeuroOne Medical Technologies had a negative net margin of 82.17% and a negative return on equity of 270.70%.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter worth about $26,000. Geode Capital Management LLC grew its holdings in NeuroOne Medical Technologies by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 283,855 shares of the company’s stock valued at $281,000 after buying an additional 24,972 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in NeuroOne Medical Technologies in the 4th quarter worth $33,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.